Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.

Di Genua C, Norfo R, Rodriguez-Meira A, Wen WX, Drissen R, Booth CAG, Povinelli B, Repapi E, Gray N, Carrelha J, Kettyle LM, Jamieson L, Neo WH, Thongjuea S, Nerlov C, Mead AJ.

Haematologica. 2019 Nov;104(11):2215-2224. doi: 10.3324/haematol.2018.205351. Epub 2019 Apr 11.

2.

Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells.

Carrelha J, Meng Y, Kettyle LM, Luis TC, Norfo R, Alcolea V, Boukarabila H, Grasso F, Gambardella A, Grover A, Högstrand K, Lord AM, Sanjuan-Pla A, Woll PS, Nerlov C, Jacobsen SEW.

Nature. 2018 Feb 1;554(7690):106-111. doi: 10.1038/nature25455. Epub 2018 Jan 3.

PMID:
29298288
3.

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.

Hay JF, Lappin K, Liberante F, Kettyle LM, Matchett KB, Thompson A, Mills KI.

Oncotarget. 2017 Jul 1;8(40):67891-67903. doi: 10.18632/oncotarget.18910. eCollection 2017 Sep 15.

4.

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.

Young CS, Clarke KM, Kettyle LM, Thompson A, Mills KI.

Oncotarget. 2017 May 19;8(31):51429-51446. doi: 10.18632/oncotarget.18009. eCollection 2017 Aug 1.

5.

Low-dose salinomycin induces anti-leukemic responses in AML and MLL.

Roulston GD, Burt CL, Kettyle LM, Matchett KB, Keenan HL, Mulgrew NM, Ramsey JM, Dougan C, McKiernan J, Grishagin IV, Mills KI, Thompson A.

Oncotarget. 2016 Nov 8;7(45):73448-73461. doi: 10.18632/oncotarget.11866.

6.

Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.

Kettyle LM, Liberante FG, Thompson A.

Methods Mol Biol. 2014;1196:349-70. doi: 10.1007/978-1-4939-1242-1_21.

PMID:
25151174
7.

c-Met inhibition in a HOXA9/Meis1 model of CN-AML.

Mulgrew NM, Kettyle LM, Ramsey JM, Cull S, Smyth LJ, Mervyn DM, Bijl JJ, Thompson A.

Dev Dyn. 2014 Jan;243(1):172-81. doi: 10.1002/dvdy.24070. Epub 2013 Dec 4.

8.

Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.

Ramsey JM, Kettyle LM, Sharpe DJ, Mulgrew NM, Dickson GJ, Bijl JJ, Austin P, Mayotte N, Cellot S, Lappin TR, Zhang SD, Mills KI, Krosl J, Sauvageau G, Thompson A.

Stem Cells. 2013 Jul;31(7):1434-45. doi: 10.1002/stem.1398.

9.

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

Dickson GJ, Liberante FG, Kettyle LM, O'Hagan KA, Finnegan DP, Bullinger L, Geerts D, McMullin MF, Lappin TR, Mills KI, Thompson A.

Haematologica. 2013 Aug;98(8):1216-25. doi: 10.3324/haematol.2012.079012. Epub 2013 Mar 28.

Supplemental Content

Loading ...
Support Center